Research ExplorerPublicationsOxidative stress in drug-naïve first episode patients with s...

Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders

Standard

Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. / Jordan, Wolfgang; Dobrowolny, Henrik; Bahn, Sabine; Bernstein, Hans-Gert; Brigadski, Tanja; Frodl, Thomas; Isermann, Berend; Lessmann, Volkmar; Pilz, Jürgen; Rodenbeck, Andrea; Schiltz, Kolja; Schwedhelm, Edzard; Tumani, Hayrettin; Wiltfang, Jens; Guest, Paul C; Steiner, Johann.

In: EUR ARCH PSY CLIN N, Vol. 268, No. 2, 03.2018, p. 129-143.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Jordan, W, Dobrowolny, H, Bahn, S, Bernstein, H-G, Brigadski, T, Frodl, T, Isermann, B, Lessmann, V, Pilz, J, Rodenbeck, A, Schiltz, K, Schwedhelm, E, Tumani, H, Wiltfang, J, Guest, PC & Steiner, J 2018, 'Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders', EUR ARCH PSY CLIN N, vol. 268, no. 2, pp. 129-143. https://doi.org/10.1007/s00406-016-0749-7

APA

Jordan, W., Dobrowolny, H., Bahn, S., Bernstein, H-G., Brigadski, T., Frodl, T., Isermann, B., Lessmann, V., Pilz, J., Rodenbeck, A., Schiltz, K., Schwedhelm, E., Tumani, H., Wiltfang, J., Guest, P. C., & Steiner, J. (2018). Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. EUR ARCH PSY CLIN N, 268(2), 129-143. https://doi.org/10.1007/s00406-016-0749-7

Vancouver

Jordan W, Dobrowolny H, Bahn S, Bernstein H-G, Brigadski T, Frodl T et al. Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. EUR ARCH PSY CLIN N. 2018 Mar;268(2):129-143. https://doi.org/10.1007/s00406-016-0749-7

Bibtex

@article{912e0c94856b45458a4800e7c6f3b1b5,
title = "Oxidative stress in drug-na{\"i}ve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders",
abstract = "Oxidative stress and immune dysregulation have been linked to schizophrenia and depression. However, it is unknown whether these factors are related to the pathophysiology or whether they are an epiphenomenon. Inconsistent oxidative stress-related findings in previous studies may have resulted from the use of different biomarkers which show disparate aspects of oxidative stress. Additionally, disease severity, medication, smoking, endocrine stress axis activation and obesity are potential confounders. In order to address some of these shortcomings, we have analyzed a broader set of oxidative stress biomarkers in our exploratory study, including urinary 8-iso-prostaglandin F2α (8-iso-PGF2α), 8-OH-2-deoyxguanosine (8-OH-2-dG), and blood levels of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione S-transferase (GST) in acutely ill drug-na{\"i}ve first episode patients with schizophrenia (n = 22), major depression (n = 18), and controls (n = 43). Possible confounding factors were considered, and patients were followed-up after 6 weeks of treatment. No differences were observed regarding 8-OH-2-dG, MDA and GST. At baseline, 8-iso-PGF2α levels were higher in patients with schizophrenia (p = 0.004) and major depression (p = 0.037), with a trend toward higher SOD concentrations in schizophrenia (p = 0.053). After treatment, schizophrenia patients showed a further increase in 8-iso-PGF2α (p = 0.016). These results were not related to age, sex, disease severity, medication or adipose tissue mass. However, 8-iso-PGF2α was associated with smoking, endocrine stress axis activation, C-reactive protein levels and low plasma concentrations of brain-derived neurotrophic factor. This study suggests a role of lipid peroxidation particularly in drug-na{\"i}ve acutely ill schizophrenia patients and highlights the importance of taking into account other confounding factors in biomarker studies.",
author = "Wolfgang Jordan and Henrik Dobrowolny and Sabine Bahn and Hans-Gert Bernstein and Tanja Brigadski and Thomas Frodl and Berend Isermann and Volkmar Lessmann and J{\"u}rgen Pilz and Andrea Rodenbeck and Kolja Schiltz and Edzard Schwedhelm and Hayrettin Tumani and Jens Wiltfang and Guest, {Paul C} and Johann Steiner",
year = "2018",
month = mar,
doi = "10.1007/s00406-016-0749-7",
language = "English",
volume = "268",
pages = "129--143",
journal = "EUR ARCH PSY CLIN N",
issn = "0940-1334",
publisher = "D. Steinkopff-Verlag",
number = "2",

}

RIS

TY - JOUR

T1 - Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders

AU - Jordan, Wolfgang

AU - Dobrowolny, Henrik

AU - Bahn, Sabine

AU - Bernstein, Hans-Gert

AU - Brigadski, Tanja

AU - Frodl, Thomas

AU - Isermann, Berend

AU - Lessmann, Volkmar

AU - Pilz, Jürgen

AU - Rodenbeck, Andrea

AU - Schiltz, Kolja

AU - Schwedhelm, Edzard

AU - Tumani, Hayrettin

AU - Wiltfang, Jens

AU - Guest, Paul C

AU - Steiner, Johann

PY - 2018/3

Y1 - 2018/3

N2 - Oxidative stress and immune dysregulation have been linked to schizophrenia and depression. However, it is unknown whether these factors are related to the pathophysiology or whether they are an epiphenomenon. Inconsistent oxidative stress-related findings in previous studies may have resulted from the use of different biomarkers which show disparate aspects of oxidative stress. Additionally, disease severity, medication, smoking, endocrine stress axis activation and obesity are potential confounders. In order to address some of these shortcomings, we have analyzed a broader set of oxidative stress biomarkers in our exploratory study, including urinary 8-iso-prostaglandin F2α (8-iso-PGF2α), 8-OH-2-deoyxguanosine (8-OH-2-dG), and blood levels of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione S-transferase (GST) in acutely ill drug-naïve first episode patients with schizophrenia (n = 22), major depression (n = 18), and controls (n = 43). Possible confounding factors were considered, and patients were followed-up after 6 weeks of treatment. No differences were observed regarding 8-OH-2-dG, MDA and GST. At baseline, 8-iso-PGF2α levels were higher in patients with schizophrenia (p = 0.004) and major depression (p = 0.037), with a trend toward higher SOD concentrations in schizophrenia (p = 0.053). After treatment, schizophrenia patients showed a further increase in 8-iso-PGF2α (p = 0.016). These results were not related to age, sex, disease severity, medication or adipose tissue mass. However, 8-iso-PGF2α was associated with smoking, endocrine stress axis activation, C-reactive protein levels and low plasma concentrations of brain-derived neurotrophic factor. This study suggests a role of lipid peroxidation particularly in drug-naïve acutely ill schizophrenia patients and highlights the importance of taking into account other confounding factors in biomarker studies.

AB - Oxidative stress and immune dysregulation have been linked to schizophrenia and depression. However, it is unknown whether these factors are related to the pathophysiology or whether they are an epiphenomenon. Inconsistent oxidative stress-related findings in previous studies may have resulted from the use of different biomarkers which show disparate aspects of oxidative stress. Additionally, disease severity, medication, smoking, endocrine stress axis activation and obesity are potential confounders. In order to address some of these shortcomings, we have analyzed a broader set of oxidative stress biomarkers in our exploratory study, including urinary 8-iso-prostaglandin F2α (8-iso-PGF2α), 8-OH-2-deoyxguanosine (8-OH-2-dG), and blood levels of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione S-transferase (GST) in acutely ill drug-naïve first episode patients with schizophrenia (n = 22), major depression (n = 18), and controls (n = 43). Possible confounding factors were considered, and patients were followed-up after 6 weeks of treatment. No differences were observed regarding 8-OH-2-dG, MDA and GST. At baseline, 8-iso-PGF2α levels were higher in patients with schizophrenia (p = 0.004) and major depression (p = 0.037), with a trend toward higher SOD concentrations in schizophrenia (p = 0.053). After treatment, schizophrenia patients showed a further increase in 8-iso-PGF2α (p = 0.016). These results were not related to age, sex, disease severity, medication or adipose tissue mass. However, 8-iso-PGF2α was associated with smoking, endocrine stress axis activation, C-reactive protein levels and low plasma concentrations of brain-derived neurotrophic factor. This study suggests a role of lipid peroxidation particularly in drug-naïve acutely ill schizophrenia patients and highlights the importance of taking into account other confounding factors in biomarker studies.

U2 - 10.1007/s00406-016-0749-7

DO - 10.1007/s00406-016-0749-7

M3 - SCORING: Journal article

C2 - 27913877

VL - 268

SP - 129

EP - 143

JO - EUR ARCH PSY CLIN N

JF - EUR ARCH PSY CLIN N

SN - 0940-1334

IS - 2

ER -